newsfilter
← Latest News
GlobeNewswire·

ContraFect to Present New Late Breaking Phase 2 Exebacase Data on Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia at IDWeek™ 2021

YONKERS, N.Y., Sept. 29, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new med